Cargando…

Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling

The BH3-only apoptosis agonists BAD and NOXA target BCL-2 and MCL-1 respectively and co-operate to induce apoptosis. On this basis, therapeutic drugs targeting BCL-2 and MCL-1 might have enhanced activity if used in combination. We identified anti-leukaemic drugs sensitising to BCL-2 antagonism and...

Descripción completa

Detalles Bibliográficos
Autores principales: Grundy, Martin, Seedhouse, Claire, Jones, Thomas, Elmi, Liban, Hall, Michael, Graham, Adam, Russell, Nigel, Pallis, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752038/
https://www.ncbi.nlm.nih.gov/pubmed/29298347
http://dx.doi.org/10.1371/journal.pone.0190682
_version_ 1783290067528187904
author Grundy, Martin
Seedhouse, Claire
Jones, Thomas
Elmi, Liban
Hall, Michael
Graham, Adam
Russell, Nigel
Pallis, Monica
author_facet Grundy, Martin
Seedhouse, Claire
Jones, Thomas
Elmi, Liban
Hall, Michael
Graham, Adam
Russell, Nigel
Pallis, Monica
author_sort Grundy, Martin
collection PubMed
description The BH3-only apoptosis agonists BAD and NOXA target BCL-2 and MCL-1 respectively and co-operate to induce apoptosis. On this basis, therapeutic drugs targeting BCL-2 and MCL-1 might have enhanced activity if used in combination. We identified anti-leukaemic drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism using the technique of dynamic BH3 profiling, whereby cells were primed with drugs to discover whether this would elicit mitochondrial outer membrane permeabilisation in response to BCL-2-targeting BAD-BH3 peptide or MCL-1-targeting MS1-BH3 peptide. We found that a broad range of anti-leukaemic agents–notably MCL-1 inhibitors, DNA damaging agents and FLT3 inhibitors–sensitise leukaemia cells to BAD-BH3. We further analysed the BCL-2 inhibitors ABT-199 and JQ1, the MCL-1 inhibitors pladienolide B and torin1, the FLT3 inhibitor AC220 and the DNA double-strand break inducer etoposide to correlate priming responses with co-operative induction of apoptosis. ABT-199 in combination with pladienolide B, torin1, etoposide or AC220 strongly induced apoptosis within 4 hours, but the MCL-1 inhibitors did not co-operate with etoposide or AC220. In keeping with the long half-life of BCL-2, the BET domain inhibitor JQ1 was found to downregulate BCL-2 and to prime cells to respond to MS1-BH3 at 48, but not at 4 hours: prolonged priming with JQ1 was then shown to induce rapid cytochrome C release when pladienolide B, torin1, etoposide or AC220 were added. In conclusion, dynamic BH3 profiling is a useful mechanism-based tool for understanding and predicting co-operative lethality between drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism. A plethora of agents sensitised cells to BAD-BH3-mediated mitochondrial outer membrane permeabilisation in the dynamic BH3 profiling assay and this was associated with effective co-operation with the BCL-2 inhibitory compounds ABT-199 or JQ1.
format Online
Article
Text
id pubmed-5752038
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57520382018-01-09 Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling Grundy, Martin Seedhouse, Claire Jones, Thomas Elmi, Liban Hall, Michael Graham, Adam Russell, Nigel Pallis, Monica PLoS One Research Article The BH3-only apoptosis agonists BAD and NOXA target BCL-2 and MCL-1 respectively and co-operate to induce apoptosis. On this basis, therapeutic drugs targeting BCL-2 and MCL-1 might have enhanced activity if used in combination. We identified anti-leukaemic drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism using the technique of dynamic BH3 profiling, whereby cells were primed with drugs to discover whether this would elicit mitochondrial outer membrane permeabilisation in response to BCL-2-targeting BAD-BH3 peptide or MCL-1-targeting MS1-BH3 peptide. We found that a broad range of anti-leukaemic agents–notably MCL-1 inhibitors, DNA damaging agents and FLT3 inhibitors–sensitise leukaemia cells to BAD-BH3. We further analysed the BCL-2 inhibitors ABT-199 and JQ1, the MCL-1 inhibitors pladienolide B and torin1, the FLT3 inhibitor AC220 and the DNA double-strand break inducer etoposide to correlate priming responses with co-operative induction of apoptosis. ABT-199 in combination with pladienolide B, torin1, etoposide or AC220 strongly induced apoptosis within 4 hours, but the MCL-1 inhibitors did not co-operate with etoposide or AC220. In keeping with the long half-life of BCL-2, the BET domain inhibitor JQ1 was found to downregulate BCL-2 and to prime cells to respond to MS1-BH3 at 48, but not at 4 hours: prolonged priming with JQ1 was then shown to induce rapid cytochrome C release when pladienolide B, torin1, etoposide or AC220 were added. In conclusion, dynamic BH3 profiling is a useful mechanism-based tool for understanding and predicting co-operative lethality between drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism. A plethora of agents sensitised cells to BAD-BH3-mediated mitochondrial outer membrane permeabilisation in the dynamic BH3 profiling assay and this was associated with effective co-operation with the BCL-2 inhibitory compounds ABT-199 or JQ1. Public Library of Science 2018-01-03 /pmc/articles/PMC5752038/ /pubmed/29298347 http://dx.doi.org/10.1371/journal.pone.0190682 Text en © 2018 Grundy et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Grundy, Martin
Seedhouse, Claire
Jones, Thomas
Elmi, Liban
Hall, Michael
Graham, Adam
Russell, Nigel
Pallis, Monica
Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
title Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
title_full Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
title_fullStr Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
title_full_unstemmed Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
title_short Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
title_sort predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic bh3 profiling
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752038/
https://www.ncbi.nlm.nih.gov/pubmed/29298347
http://dx.doi.org/10.1371/journal.pone.0190682
work_keys_str_mv AT grundymartin predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling
AT seedhouseclaire predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling
AT jonesthomas predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling
AT elmiliban predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling
AT hallmichael predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling
AT grahamadam predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling
AT russellnigel predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling
AT pallismonica predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling